Search details
1.
Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial.
J Infect Dis
; 2024 Mar 25.
Article
in English
| MEDLINE | ID: mdl-38527849
2.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med
; 385(25): 2348-2360, 2021 12 16.
Article
in English
| MEDLINE | ID: mdl-34587382
3.
A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study.
Br J Clin Pharmacol
; 89(3): 1187-1197, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36199201
4.
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
N Engl J Med
; 380(3): 229-241, 2019 01 17.
Article
in English
| MEDLINE | ID: mdl-30650326
5.
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
N Engl J Med
; 380(3): 215-228, 2019 01 17.
Article
in English
| MEDLINE | ID: mdl-30650322
6.
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.
Pharmacogenet Genomics
; 30(7): 161-165, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32433338
7.
Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data.
Bull World Health Organ
; 97(12): 828-836, 2019 Dec 01.
Article
in English
| MEDLINE | ID: mdl-31819291
8.
Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.
Antimicrob Agents Chemother
; 62(11)2018 11.
Article
in English
| MEDLINE | ID: mdl-30201820
9.
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
N Engl J Med
; 380(19): 1876, 2019 05 09.
Article
in English
| MEDLINE | ID: mdl-31067385
10.
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
J Infect Dis
; 213(5): 794-9, 2016 Mar 01.
Article
in English
| MEDLINE | ID: mdl-26500351
11.
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Antimicrob Agents Chemother
; 60(12): 7321-7332, 2016 12.
Article
in English
| MEDLINE | ID: mdl-27697758
12.
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
Malar J
; 15: 97, 2016 Feb 18.
Article
in English
| MEDLINE | ID: mdl-26888075
13.
Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria.
Antimicrob Agents Chemother
; 59(10): 6188-94, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26248362
14.
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Lancet
; 383(9922): 1049-58, 2014 Mar 22.
Article
in English
| MEDLINE | ID: mdl-24360369
15.
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.
Front Immunol
; 15: 1401728, 2024.
Article
in English
| MEDLINE | ID: mdl-38827749
16.
Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'.
Elife
; 132024 Feb 07.
Article
in English
| MEDLINE | ID: mdl-38323801
17.
In an in vitro model of human tuberculosis, monocyte-microglial networks regulate matrix metalloproteinase-1 and -3 gene expression and secretion via a p38 mitogen activated protein kinase-dependent pathway.
J Neuroinflammation
; 10: 107, 2013 Aug 26.
Article
in English
| MEDLINE | ID: mdl-23978194
18.
Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites.
medRxiv
; 2023 Mar 16.
Article
in English
| MEDLINE | ID: mdl-36993192
19.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Lancet Microbe
; 4(11): e863-e874, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37783221
20.
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Lancet Infect Dis
; 23(10): 1153-1163, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37236221